Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating
persistent microalbuminuria in type 2 diabetic patients who are also being treated with
stable, maximum tolerated doses of either ACE inhibitors or A2 receptor blockers.